
Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market
Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China…

Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China…

Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive…

The breast cancer drug list in China mainly includes endocrine therapy drugs, HER2-targeted drugs, CDK4/6…

Key Takeaways Melanoma is a malignant tumor that originates from melanocytes and most commonly develops…

What are the most common chemotherapy drugs? Common chemotherapy drugs include Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel,…

Recibokibart approved for GPP marks a major milestone in Generalized Pustular Psoriasis (GPP) treatment. Developed…

Common drugs for prostate cancer include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs),…

Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted…

Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor,…

Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R)…